---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002672"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T15:00:28.405160+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anika Therapeutics Q1 revenue up 7% to $40.5M; narrows net loss; reaffirms FY2024 guidance

## Summary
- Q1 revenue $40.5M (+7% YoY); net loss narrowed to $4.5M from $10.4M; adjusted net income $1.2M ($0.09/dil share).
- Adjusted EBITDA improved to $2.5M from ($1.2M) in Q1 2023; FY2024 adj EBITDA guidance $25-30M (midpoint up >75%).
- Cost reduction initiatives completed, achieving $10M annualized savings; severance costs $0.8M in Q1.
- Business highlights: extended Canadian distribution deal through 2030; >10,000 X-Twist anchors sold; Integrity Implant >200 cases.

## SEC filing metadata
- accession: 0001171843-24-002672
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184324002672/0001171843-24-002672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184324002672/f8k_050824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002672
- JSON: https://secwatch.observer/filing/0001171843-24-002672.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002672.txt

## Key facts
- Earnings Releases
  Anika Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $40.5 million, net income $(4.5) million, or ($0.31) per share, EPS $0.09 per diluted share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $40.5 million
  - Net income: $(4.5) million, or ($0.31) per share
  - EPS: $0.09 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: orthopedics, today reported financial results for its first quarter ended March 31, 2024. First Quarter 2024 Financial Summary Revenue in the first quarter of 2024 was $40.5 million, up 7% compared to $37.9 million in the first quarter of 2023. OA Pain Management revenue of $24.3 million, up 7% Joint Preservation and Restoration revenue of $13.8 million, up
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184324002672/0001171843-24-002672-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.